Transdermal Specialties Global (TSG) is a pioneering drug delivery company located in Frederick, MD, using a unique and patented technology that dramatically increases the number of drugs which can be delivered with a transdermal patch-No More Needles. TSG’s lead product is a painless Transdermal Insulin Patch, now in Phase-3 clinical stage in both the United States and in South Korea.
Insulin is too large a molecule to work with a conventional patch. The U-Strip™ uses a special, patented, ultrasonic technique to dilate the skin pores and push the compound into the blood stream. There are over 30 million diabetics in the US, 90% are Type-2, who use insulin needles, pumps or oral meds to control their glucose. The needle and the pump are highly invasive. The orals are often hard to maintain on a dosing schedule and lead to compliance problems. The complexities and burden of current insulin regimens often result in an irregular control of the diabetic glucose condition. The U-Strip™ Transdermal Insulin Patch system makes for an easier maintenance of glucose, with a set-it-and-forget-it easy to use patch technology, all with no skin penetration.
Besides Insulin the company is producing additional transdermal patch products for Parkinson’s, Severe Migraine, Multiple Sclerosis, along with 175 other Rx possibilities where the drug is too large to pass through skin using conventional patch technology but can with the U-Strip™.
Bruce K. Redding, Jr, (CEO) will lead a detailed virtual event on how the U-Strip™ can dramatically increase the number of drugs which can be delivered through a patch, from the current 25 patch products to over 175 Rx Targets. Interested Investors or Medical Personnel are invited to tune in to this presentation to learn more about this unique and emerging drug delivery system.